Teva stalled out? Maybe? Like the rest of the space, TEVA has had a nice ride, but maybe time to step aside. See the article and chart.   Don't be surprised if Teva's ($TEVA) revenue numbers don't meet analysts' expectations in 2015. According to the company's forecasts, generic competition to top-seller Copaxone and foreign currency [...]